Huang Jiayu, Xiao Zhenke, Lao Junming, Pan Lingli, Chen Zhou, Lin Zehua
The Affiliated Traditional Chinese Medicine Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510130, China.
BMC Anesthesiol. 2025 Jul 1;25(1):329. doi: 10.1186/s12871-025-03197-6.
This meta-analysis evaluated the effectiveness of remimazolam compared to propofol in preventing postoperative delirium among elderly surgical patients.
We systematically searched PubMed, CNKI, Cochrane Library, Web of Science, Embase, Wangfang, and VIP for randomized controlled trials (RCTs) comparing remimazolam and propofol for postoperative delirium prevention in elderly surgical patients (last search: July 27, 2024). Data were analyzed using Stata 15.0.
Eight randomized controlled trials (2,013 participants; remimazolam = 1,034, propofol = 979) found no significant differences in postoperative delirium incidence [RR = 0.67,95%CI(0.45–1.01)], severity [WMD=-0.28,95%CI(-0.61-0.04)], or duration [WMD=-0.06,95%CI(-0.15-0.03)], nor in postoperative pain VAS scores [WMD=-0.08,95%CI(-0.18-0.02)]. remimazolam significantly reduced postoperative hypotension risk compared to propofol [RR = 0.48,95%CI(0.29–0.80)], demonstrating improved safety.
This meta-analysis demonstrates comparable efficacy between remimazolam and propofol in preventing postoperative delirium, with remimazolam demonstrating superior safety through significantly lower postoperative hypotension rates.
The online version contains supplementary material available at 10.1186/s12871-025-03197-6.
本荟萃分析评估了瑞马唑仑与丙泊酚相比,在预防老年外科手术患者术后谵妄方面的有效性。
我们系统检索了PubMed、中国知网、考克兰图书馆、科学网、Embase、万方和维普,以查找比较瑞马唑仑和丙泊酚预防老年外科手术患者术后谵妄的随机对照试验(RCT)(最后检索时间:2024年7月27日)。使用Stata 15.0进行数据分析。
八项随机对照试验(2013名参与者;瑞马唑仑=1034,丙泊酚=979)发现,术后谵妄发生率[RR=0.67,95%CI(0.45-1.01)]、严重程度[WMD=-0.28,95%CI(-0.61-0.04)]或持续时间[WMD=-0.06,95%CI(-0.15-0.03)]均无显著差异,术后疼痛视觉模拟量表评分[WMD=-0.08,95%CI(-0.18-0.02)]也无显著差异。与丙泊酚相比,瑞马唑仑显著降低了术后低血压风险[RR=0.48,95%CI(0.29-0.80)],表明安全性有所提高。
本荟萃分析表明,瑞马唑仑和丙泊酚在预防术后谵妄方面疗效相当,瑞马唑仑通过显著降低术后低血压发生率显示出更高的安全性。
在线版本包含可在10.1186/s12871-025-03197-6获取的补充材料。